Mumbai, April 17 -- Lupin Pharmaceuticals, Inc. USA (LPI), a wholly owned subsidiary of the Company, has been involved in multiple civil lawsuits alleging anticompetitive behavior related to certain products and violation of federal and state antitrust laws. These multiple civil lawsuits were then combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation (Litigation), located in Philadelphia, Pennsylvania.

Published by HT Digital Content Services with permission from Capital Market....